Vincristine Dose Cap Associated With Reduced Incidence of Neuropathies With DA-EPOCH-R for Aggressive Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Impact of a Vincristine Dose Cap on the Incidence of Neuropathies With DA-EPOCH-R for the Treatment of Aggressive Lymphomas
Leukemia and Lymphoma 2019 Dec 26;[EPub Ahead of Print], TM Weis, BL Marini, VR Nachar, AM Brown, TJ Phillips, J Brown, RA Wilcox, MS Kaminski, S Devata, AJ PerissinottiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.